Key Takeaways

  • OXB signed 17 new clients in H1 2026, 30% above its entire 2025 total, with its new Business pipeline rising to approximately $713 million.
  • Full-year 2026 Revenue guidance was cut to £180-200 million, down from £220-240 million, due to programme deferrals and a client's procurement strategy shift.
  • H1 2026 revenue rose 9% to approximately £80 million, but net cash nearly halved to £21 million from £55 million at end-2025.
  • A six-month delay integrating the Durham, North Carolina site acquired in October 2025 has weighed on near-term capacity, though the first GMP run is now under way.
  • FY2025 revenue reached £168.7 million, up 31%, but the group posted an operating loss of £22.5 million and a net loss of £30.6 million.

Oxford Biomedica (LSE:OXB), the Oxford-based contract development and Manufacturing organisation (CDMO) known to the market as OXB, delivered a mixed message to investors on 7 August 2026. A half-year trading update showed the business signing new clients at its fastest pace on record, yet also confirmed that full-year revenue guidance has been cut materially. For a company that spent 2025 rebuilding its reputation as a pure-play viral vector manufacturer, the update is a reminder that commercial momentum and revenue delivery do not always move together in the cell and gene therapy CDMO sector.

What Happened

In its Half Year Trading Update and Notice of Results, OXB reported that it signed 17 new clients in the six months to 30 June 2026 - a figure the company said was 30% above its entire new-client total for the whole of 2025. Its new business pipeline rose to approximately $713 million, up around 30% year-on-year.

Set against that, OXB reduced its full-year 2026 revenue guidance to £180-200 million, down from the £220-240 million range set out at its February 2026 full-year trading update and reiterated in March. It attributed the cut to "deferrals and delayed timelines of selected programmes in 2026 due to changes in client strategy or clinical data", plus a shift in procurement strategy and approval pathway for a larger client. It also flagged a six-month delay integrating its Durham, North Carolina site, acquired in October 2025, though the first GMP run there is now under way. Full interim results are due on 22 September 2026.

Why It Matters

The downgrade matters because OXB had built its 2026 guidance around a first full year as a "pure-play" CDMO following its 2023 divestment of in-house gene therapy Assets . Investors had been asked to underwrite an ambitious ramp: 25-30% revenue growth in 2027 and a longer-term target of roughly £500 million in annual revenue by 2030. A cut of this scale - around £40 million off both ends of the range, within months of setting it - raises questions about order-timing predictability in a business reliant on discrete manufacturing campaigns rather than recurring income. Record client signings suggest underlying Demand for viral vector capacity remains intact, making this look more like phasing than a structural loss of business.

Latest Financial and Operational Performance

OXB reported H1 2026 revenue of approximately £80 million, up 9% year-on-year. Revenue Backlog stood at £193 million, with contracted client orders of £97 million, together covering an estimated £165 million of the revised 2026 forecast. Cash reserves declined over the half: gross cash fell to £75 million from £97 million at end-2025, while net cash dropped to £21 million from £55 million.

This follows a strong 2025. Full-year revenue reached £168.7 million, up 31%, landing at the upper end of prior guidance. Operating EBITDA was £2.3 million, though the underlying figure, stripping out a one-off Durham-linked gain, was £3.3 million at constant currency. The group still posted an operating loss of £22.5 million and a net loss of £30.6 million. Year-end headcount rose to 986 from 861. Contracted client orders at end-2025 stood at £224 million, up 20%, with a pipeline then valued at $597 million.

Key Numbers

  • H1 2026 revenue: approximately £80 million, up 9% year-on-year
  • New clients signed in H1 2026: 17 (30% above the full-year 2025 total)
  • New business pipeline: approximately $713 million, up around 30% year-on-year
  • Revised FY2026 revenue guidance: £180-200 million (down from £220-240 million)
  • Gross cash: £75 million at H1 2026 (£97 million end-2025); net cash £21 million (£55 million end-2025)
  • FY2025 revenue: £168.7 million, up 31%
  • FY2025 headcount: 986 (up from 861 in 2024)
  • 2030 revenue ambition: approximately £500 million

Growth Opportunities

Oxford Biomedica (LSE:OXB) continues to add to its client base and geographic reach. In July 2026 it signed a manufacturing agreement with Plowshare Therapies to provide process development and AAV GMP manufacturing for PLOW-101, a gene therapy for maple syrup urine disease, to be produced at Durham - evidence the newly acquired site is winning client business despite the integration delay. In March 2026, OXB licensed its inAAVate AAV platform, with an option over its LentiVector platform, to Australia's VVMF for a low single-digit million fee plus future usage-linked payments, extending its footprint into Asia-Pacific without Capital outlay. April 2026 saw the launch of a "fast-track" viral vector offering for eligible biotech clients. Management has reiterated ambitions of 25-30% revenue growth in 2027 and double-digit EBITDA margins, underpinned by AAV work that made up more than half of new business wins in 2025.

Risks Investors Should Know

The central risk is revenue lumpiness: OXB's income depends on the timing of client orders, and a small number of programme deferrals or a change in one large client's approval pathway can materially move full-year guidance, as the August update shows. The Durham delay illustrates execution risk around recent acquisitions. Cash generation bears watching too - net cash nearly halved in the first half of 2026 - while the group remains loss-making at the operating and net level despite double-digit revenue growth. Guidance credibility is now a live issue: having cut its outlook within months of setting it, OXB must show the revised range is durable when it reports interim results in September.

What to Watch Next

Investors should watch the 22 September interim results for a fuller picture of margins, Cash Flow and order conversion, plus any update on how quickly Durham scales towards capacity. Progress converting the $713 million pipeline into contracted orders, and whether further client deferrals emerge, will indicate whether the guidance cut proves a one-off timing issue or tougher near-term demand.

Outlook

OXB's half-year update captures the tension inherent in scaling a CDMO business: client-facing momentum, evidenced by record new-client signings and a growing pipeline, has not yet translated into the revenue certainty investors were promised at the start of the year. Whether the £180-200 million guidance holds through September's interim results will determine whether this is remembered as a temporary setback or the start of a more cautious chapter for the company's pure-play strategy.

Q; What did Oxford BioMedica's H1 2026 results show?